Our portfolio company, AVA participates in the COVI-GAPP study recently launched by Liechtenstein scientists and entrepreneurs Professor Dr. Lorenz Risch and Dr. Martin Risch.
The AVA bracelet, developed for women’s reproductive health, would function as an early warning system giving healthcare professionals information about the condition of individuals infected with Covid-19 without them having to come into direct contact with these individuals or exposing themselves to possible infection.
On April 16, 2020 an article in the Financial Times explained how Liechtenstein rolls out a radical Covid-19 programme by providing AVA bracelet to 1 in 20 women in the country.
We congratulate AVA for its collaboration to this great initiative.
Read the AVA article.
Read about the COVI-GAPP study.